vs
Side-by-side financial comparison of IHS Holding Ltd (IHS) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
IHS Holding Ltd is the larger business by last-quarter revenue ($254.0M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 0.1%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -22.0%).
IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world, with operations across Africa and Latin America. It is the fifth-largest independent multinational tower company in the world.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
IHS vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $254.0M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | 83.6% | — |
| Operating Margin | — | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 0.1% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $254.0M | $196.9M | ||
| Q3 25 | $455.1M | $179.5M | ||
| Q2 25 | $433.3M | $181.1M | ||
| Q1 25 | $439.6M | $168.9M | ||
| Q4 24 | $253.8M | $187.3M | ||
| Q3 24 | $420.3M | $168.6M | ||
| Q2 24 | $435.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $147.4M | $5.4M | ||
| Q2 25 | $32.3M | $-4.8M | ||
| Q1 25 | $30.7M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-205.7M | $-143.5M | ||
| Q2 24 | $-124.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 83.6% | 79.5% | ||
| Q3 25 | 47.5% | 80.9% | ||
| Q2 25 | 51.3% | 77.4% | ||
| Q1 25 | 51.4% | 79.7% | ||
| Q4 24 | 72.1% | 78.7% | ||
| Q3 24 | 52.0% | 76.9% | ||
| Q2 24 | 52.5% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 35.1% | 3.5% | ||
| Q2 25 | 33.8% | 4.7% | ||
| Q1 25 | 37.1% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 29.9% | -82.8% | ||
| Q2 24 | 34.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 32.4% | 3.0% | ||
| Q2 25 | 7.5% | -2.7% | ||
| Q1 25 | 7.0% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -48.9% | -85.1% | ||
| Q2 24 | -28.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.44 | $0.12 | ||
| Q2 25 | $0.10 | $-0.11 | ||
| Q1 25 | $0.10 | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $-0.61 | $-3.11 | ||
| Q2 24 | $-0.36 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $825.7M | $144.3M |
| Total DebtLower is stronger | $3.1B | — |
| Stockholders' EquityBook value | $-89.8M | $653.9M |
| Total Assets | $4.5B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $825.7M | $238.4M | ||
| Q3 25 | $647.6M | $246.3M | ||
| Q2 25 | $531.8M | $445.9M | ||
| Q1 25 | $629.0M | $493.6M | ||
| Q4 24 | $578.0M | $484.6M | ||
| Q3 24 | $397.5M | $453.8M | ||
| Q2 24 | $445.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $372.2M | ||
| Q3 25 | $3.3B | $376.7M | ||
| Q2 25 | $3.2B | $580.5M | ||
| Q1 25 | $3.4B | $583.4M | ||
| Q4 24 | $3.3B | $585.3M | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.6B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-89.8M | $693.1M | ||
| Q3 25 | $38.1M | $727.2M | ||
| Q2 25 | $-98.4M | $757.8M | ||
| Q1 25 | $-184.4M | $798.5M | ||
| Q4 24 | $-314.4M | $778.3M | ||
| Q3 24 | $-284.7M | $749.6M | ||
| Q2 24 | $-308.3M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.5B | $1.3B | ||
| Q3 25 | $4.7B | $1.3B | ||
| Q2 25 | $4.5B | $1.5B | ||
| Q1 25 | $4.4B | $1.6B | ||
| Q4 24 | $4.2B | $1.6B | ||
| Q3 24 | $4.6B | $1.5B | ||
| Q2 24 | $4.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | 85.85× | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $246.9M | — |
| Free Cash FlowOCF − Capex | $178.6M | — |
| FCF MarginFCF / Revenue | 70.3% | — |
| Capex IntensityCapex / Revenue | 26.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $718.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $246.9M | $43.7M | ||
| Q3 25 | $251.3M | $60.8M | ||
| Q2 25 | $237.7M | $12.0M | ||
| Q1 25 | $200.3M | $35.5M | ||
| Q4 24 | $344.4M | $33.1M | ||
| Q3 24 | $174.5M | $53.9M | ||
| Q2 24 | $134.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $178.6M | $43.5M | ||
| Q3 25 | $189.2M | $57.0M | ||
| Q2 25 | $197.7M | $9.3M | ||
| Q1 25 | $153.2M | $26.9M | ||
| Q4 24 | $282.9M | $31.0M | ||
| Q3 24 | $122.3M | $49.8M | ||
| Q2 24 | $74.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 70.3% | 22.1% | ||
| Q3 25 | 41.6% | 31.7% | ||
| Q2 25 | 45.6% | 5.1% | ||
| Q1 25 | 34.8% | 15.9% | ||
| Q4 24 | 111.5% | 16.6% | ||
| Q3 24 | 29.1% | 29.6% | ||
| Q2 24 | 17.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 26.9% | 0.1% | ||
| Q3 25 | 13.6% | 2.2% | ||
| Q2 25 | 9.2% | 1.5% | ||
| Q1 25 | 10.7% | 5.1% | ||
| Q4 24 | 24.2% | 1.1% | ||
| Q3 24 | 12.4% | 2.4% | ||
| Q2 24 | 13.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.70× | 11.20× | ||
| Q2 25 | 7.36× | — | ||
| Q1 25 | 6.52× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IHS
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
